Pregnancy is no longer medically unadvised, or contraindicated, as it once was, for women with a history of atypical…
Articles by Marta Figueiredo, PhD
The first wave of COVID-19Â in Europe severely disrupted access to care and raised stress and anxiety in people with…
Extending the dosing interval of Soliris (eculizumab) maintenance treatment from standard two weeks to three weeks may equally…
Self-administering Ultomiris (ravulizumab) as weekly under-the-skin injections may be as safe and effective in preventing overactivation of the…
Alexion Pharmaceuticals announced that Ultomiris (ravulizumab) has been approved in the European Union to treat adults and children…
Mutations in the CD46 gene — a regulator of the complement system — may lead to pregnancy-associated atypical…
Soliris (eculizumab) maintenance treatment given every three weeks — instead of the standard two weeks — was sufficient to…
Pregnancy-associated atypical hemolytic uremic syndrome (aHUS) usually occurs postpartum, after a pregnancy complication — such as preeclampsia, severe…
Alexion Pharmaceuticals now holds exclusive rights to Dicerna’s potential RNA interference (RNAi) therapies developed against four targets…
Plasma exchange (PEX) therapy given before and after kidney transplants reduces the risk of disease relapse and transplant failure…